Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 2
2011 2
2012 6
2013 15
2014 32
2015 28
2016 30
2017 42
2018 42
2019 43
2020 55
2021 44
2022 49
2023 58
2024 80
2025 61
2026 43

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

558 results

Results by year

Filters applied: . Clear all
Page 1
Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Citrome L, Sakuma K, Hatano M, Hamanaka S, Nishii Y, Iwata N. Kishi T, et al. Transl Psychiatry. 2025 Jun 24;15(1):211. doi: 10.1038/s41398-025-03439-8. Transl Psychiatry. 2025. PMID: 40555730 Free PMC article.
BACKGROUND: In order to appraise the risk-benefit balance of the three available dual orexin receptor antagonists (DORAs; daridorexant, lemborexant, and suvorexant) for the management of adults with insomnia, we conducted a systematic review and random-effects model networ …
BACKGROUND: In order to appraise the risk-benefit balance of the three available dual orexin receptor antagonists (DORAs; daridorexant, lemb …
Suvorexant.
[No authors listed] [No authors listed] 2025 Jun 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2025 Jun 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 34958536 Free Books & Documents. Review.
The amounts of suvorexant in milk are very low. If suvorexant is required by the mother, it is not a reason to discontinue breastfeeding. If suvorexant is used, monitor the infant for sedation, especially if the infant is a newborn or preterm....
The amounts of suvorexant in milk are very low. If suvorexant is required by the mother, it is not a reason to discontinue bre …
Suvorexant Acutely Decreases Tau Phosphorylation and Abeta in the Human CNS.
Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barthélemy NR, Bateman RJ. Lucey BP, et al. Ann Neurol. 2023 Jul;94(1):27-40. doi: 10.1002/ana.26641. Epub 2023 Apr 20. Ann Neurol. 2023. PMID: 36897120 Free PMC article. Clinical Trial.
In this randomized controlled trial, we tested the acute effect of suvorexant, a dual orexin receptor antagonist, on amyloid-beta, tau, and phospho-tau. METHODS: Thirty-eight cognitively unimpaired participants aged 45 to 65 years were randomized to placebo (N = 13), su …
In this randomized controlled trial, we tested the acute effect of suvorexant, a dual orexin receptor antagonist, on amyloid-beta, ta …
Suvorexant.
[No authors listed] [No authors listed] 2025 Feb 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2025 Feb 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643236 Free Books & Documents. Review.
Suvorexant is an orexin receptor antagonist used for the treatment of insomnia and sleep disorders. Suvorexant therapy is associated with rare occurrence of transient serum enzyme elevations but has not been implicated in cases of clinically apparent liver injury... …
Suvorexant is an orexin receptor antagonist used for the treatment of insomnia and sleep disorders. Suvorexant therapy is asso …
Suvorexant for the prevention of delirium: A meta-analysis.
Xu S, Cui Y, Shen J, Wang P. Xu S, et al. Medicine (Baltimore). 2020 Jul 24;99(30):e21043. doi: 10.1097/MD.0000000000021043. Medicine (Baltimore). 2020. PMID: 32791676 Free PMC article. Review.
RESULTS: Seven studies which comprised 402 suvorexant treatment patients and 487 patients with control treatment were included in this meta-analysis. ...Subgroup analysis also confirmed the benefit of suvorexant on the development of delirium, which was significant …
RESULTS: Seven studies which comprised 402 suvorexant treatment patients and 487 patients with control treatment were included in thi …
Suvorexant for Reduction of Delirium in Older Adults After Hospitalization: A Randomized Clinical Trial.
Hatta K, Kishi Y, Wada K, Takeuchi T, Taira T, Uemura K, Ogawa A, Takahashi K, Sato A, Shirakawa M, Herring WJ, Arano I; Suvorexant 085 Study Group. Hatta K, et al. JAMA Netw Open. 2024 Aug 1;7(8):e2427691. doi: 10.1001/jamanetworkopen.2024.27691. JAMA Netw Open. 2024. PMID: 39150711 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the orexin receptor antagonist suvorexant for reducing delirium in older adults at high risk for delirium after hospitalization. ...CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of suvorexant in older adults at high risk for del …
OBJECTIVE: To evaluate the orexin receptor antagonist suvorexant for reducing delirium in older adults at high risk for delirium afte …
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D. Herring WJ, et al. Biol Psychiatry. 2016 Jan 15;79(2):136-48. doi: 10.1016/j.biopsych.2014.10.003. Epub 2014 Oct 23. Biol Psychiatry. 2016. PMID: 25526970 Clinical Trial.
BACKGROUND: Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials. ...The results did not suggest the emergence of marked rebound or withdrawal signs or symptoms when suvorexant was discontinued. CON …
BACKGROUND: Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials. …
Suvorexant.
[No authors listed] [No authors listed] Aust Prescr. 2017 Jun;40(3):116-117. doi: 10.18773/austprescr.2017.040. Epub 2017 May 10. Aust Prescr. 2017. PMID: 28798520 Free PMC article. Review. No abstract available.
Efficacy of Ramelteon, Suvorexant, and Lemborexant for Delirium Prevention in Hospitalized Patients: A Systematic Review and Meta-Analysis.
de Oliveira HM, Gallo Ruelas M, Zamora FV, Oliveira de Paula G, Oliveira Fonseca PE, Luiz L, Fruett da Costa PR. de Oliveira HM, et al. Crit Care Med. 2025 Sep 1;53(9):e1781-e1789. doi: 10.1097/CCM.0000000000006737. Epub 2025 Jun 13. Crit Care Med. 2025. PMID: 40511987
Our objective was to evaluate the preventive efficacy of suvorexant, lemborexant, and ramelteon in reducing delirium prevalence and associated clinical outcomes. ...STUDY SELECTION: Randomized controlled trials or observational studies involving hospitalized adults assessi …
Our objective was to evaluate the preventive efficacy of suvorexant, lemborexant, and ramelteon in reducing delirium prevalence and a …
Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
Berger AA, Sottosanti ER, Winnick A, Keefe J, Gilbert E, Hasoon J, Thase ME, Kaye AD, Viswanath O, Urits I. Berger AA, et al. Psychopharmacol Bull. 2022 Feb 25;52(1):68-90. doi: 10.64719/pb.4429. Psychopharmacol Bull. 2022. PMID: 35342199 Free PMC article. Review.
SUMMARY: Multiple clinical studies support the use of suvorexant in insomnia. In primary insomnia, suvorexant is effective (over placebo), as measured by polysomnography and reported by patients, in both attaining and maintaining sleep. ...Unfortunately, data exists …
SUMMARY: Multiple clinical studies support the use of suvorexant in insomnia. In primary insomnia, suvorexant is effective (ov …
558 results